![]() Tissue Engineering and Regeneration Market Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Biomaterials, Cell Therapy, Tissue Engineering), by Application (Orthopedics, Dermatology, Cardiology, Neurology, Others), By Region & Competition, 2020-2030F
Global Tissue Engineering and Regeneration Market was valued at USD 14.57 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.35% through 2030... もっと見る
SummaryGlobal Tissue Engineering and Regeneration Market was valued at USD 14.57 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.35% through 2030. Tissue Engineering and Regeneration are fields of biomedical science and engineering that focus on the development of biological substitutes to repair or replace damaged or diseased tissues and organs in the human body. These fields aim to restore normal tissue function, promote healing, and improve the quality of life for patients suffering from a wide range of medical conditions. Tissue engineering is the science and practice of creating functional and living tissues or organs using a combination of cells, biomaterials, and biochemical factors.Key Market Drivers High Demand for Organ Transplants The demand for organ transplants far exceeds the supply of available donor organs. This shortage of organs for transplantation has led to long waiting lists, and many patients may not receive a transplant in time. Tissue engineering offers a potential solution to address this organ shortage by creating lab-grown organs and tissues. Tissue engineering and regenerative medicine techniques involve growing functional organs and tissues in the laboratory using a patient's cells or other biocompatible materials. This approach provides an alternative source of organs for transplantation, reducing the dependence on donor organs. Tissue engineering allows for the creation of personalized organs that can be tailored to individual patients. This reduces the risk of organ rejection and the need for long-term immunosuppressive medications, which are necessary in traditional organ transplantation. Tissue engineering can create organs that are traditionally challenging to obtain from donors, such as vascularized organs, like hearts and kidneys. This expands the range of available organs for transplantation. In January 2023, a research team led by Dr. Hasan Erbil Abaci at Columbia University began developing techniques to create 3D-engineered skin customized for complex body parts. These tailored grafts can be transplanted with minimal suturing, improving surgical efficiency and outcomes. Key Market Challenges Long and Expensive Development Process The development of regenerative therapies begins with extensive research and preclinical testing to understand the safety and efficacy of the proposed treatments. This stage can take many years and involve substantial financial resources. Clinical trials are a critical step in the development process to demonstrate the safety and effectiveness of regenerative therapies in humans. Conducting these trials involves a substantial investment, takes several years, and requires compliance with stringent regulatory requirements. Obtaining regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) is a lengthy and costly process. Companies must meet rigorous standards and provide comprehensive data to prove the safety and efficacy of their therapies. Transitioning from small-scale laboratory production to large-scale manufacturing can be challenging. Ensuring consistent and cost-effective production of regenerative therapies is a complex task. Maintaining quality control and standardization throughout the manufacturing process is crucial. Deviations can lead to product inconsistency and may pose risks to patient safety. The development of regenerative therapies requires substantial financial resources, including funding for research, clinical trials, manufacturing facilities, and regulatory compliance. Raising this capital can be a barrier to entry for startups and smaller companies. Many regenerative therapies do not successfully make it to market. The high failure rate in clinical trials and the lengthy timelines contribute to the overall cost of development. The long development process can result in market uncertainties. By the time a therapy reaches the market, changes in the competitive landscape or evolving clinical standards can impact its commercial success. Key Market Trends Personalized Medicine Tissue engineering and regenerative medicine aim to create therapies that are customized to each patient's unique needs. This approach can address individual variations in health, genetics, and disease. Induced pluripotent stem cells (iPSCs) are reprogrammed from a patient's own cells and can be used to generate patient-specific tissues and organs. This minimizes the risk of immune rejection and graft-versus-host disease. Advancements in genomics and molecular profiling allow for a detailed analysis of a patient's genetic and molecular characteristics. This information is used to guide treatment decisions and tailor regenerative therapies. iPSCs and patient-derived cells are used to create disease models, enabling researchers to study diseases in a patient-specific context. This is valuable for understanding disease mechanisms and testing potential treatments. Personalized regenerative therapies reduce the risk of immune rejection, as they are based on the patient's own cells. This minimizes the need for immunosuppressive drugs. By understanding a patient's genetic and molecular profile, clinicians can optimize the choice of tissue engineering and regenerative therapies. This ensures that the treatment is more likely to be effective and safe for the individual patient. Personalized medicine allows clinicians to predict a patient's response to specific therapies, helping to select the most appropriate regenerative approach for a better outcome. Personalized medicine places the patient at the center of care, emphasizing tailored treatments that consider the patient's unique biology, preferences, and needs. In some cases, companion diagnostics are used to identify the most suitable regenerative therapy for a patient based on their genetic or molecular profile. Key Market Players • Organogenesis Inc. • Acelity L.P. Inc. • Zimmer Biomet Holdings Inc. • Stryker Corporation • Integra LifeSciences Holdings Corporation • Medtronic plc • Smith & Nephew plc • Athersys Inc. • Vericel Corporation • Osiris Therapeutics, Inc. Report Scope: In this report, the Global Tissue Engineering and Regeneration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: • Tissue Engineering and Regeneration Market, By Product: o Biomaterials o Cell Therapy o Tissue Engineering · Tissue Engineering and Regeneration Market, By Application: o Orthopedics o Dermatology o Cardiology o Neurology o Others • Tissue Engineering and Regeneration Market, By region: o North America § United States § Canada § Mexico o Asia-Pacific § China § India § South Korea § Australia § Japan o Europe § Germany § France § United Kingdom § Spain § Italy o South America § Brazil § Argentina § Colombia o Middle East & Africa § South Africa § Saudi Arabia § UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies presents in the Global Tissue Engineering and Regeneration Market. Available Customizations: Global Tissue Engineering and Regeneration Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information • Detailed analysis and profiling of additional market players (up to five). Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Global Tissue Engineering and Regeneration Market Outlook 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Product (Biomaterials, Cell Therapy, Tissue Engineering) 5.2.2. By Application (Orthopedics, Dermatology, Cardiology, Neurology, Others) 5.2.3. By Region 5.2.4. By Company (2024) 5.3. Market Map 6. Asia Pacific Tissue Engineering and Regeneration Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Product 6.2.2. By Application 6.2.3. By Country 6.3. Asia Pacific: Country Analysis 6.3.1. China Tissue Engineering and Regeneration Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Product 6.3.1.2.2. By Application 6.3.2. India Tissue Engineering and Regeneration Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. By Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Product 6.3.2.2.2. By Application 6.3.3. Australia Tissue Engineering and Regeneration Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Product 6.3.3.2.2. By Application 6.3.4. Japan Tissue Engineering and Regeneration Market Outlook 6.3.4.1. Market Size & Forecast 6.3.4.1.1. By Value 6.3.4.2. Market Share & Forecast 6.3.4.2.1. By Product 6.3.4.2.2. By Application 6.3.5. South Korea Tissue Engineering and Regeneration Market Outlook 6.3.5.1. Market Size & Forecast 6.3.5.1.1. By Value 6.3.5.2. Market Share & Forecast 6.3.5.2.1. By Product 6.3.5.2.2. By Application 7. Europe Tissue Engineering and Regeneration Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Product 7.2.2. By Application 7.2.3. By Country 7.3. Europe: Country Analysis 7.3.1. France Tissue Engineering and Regeneration Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Product 7.3.1.2.2. By Application 7.3.2. Germany Tissue Engineering and Regeneration Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Product 7.3.2.2.2. By Application 7.3.3. Spain Tissue Engineering and Regeneration Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Product 7.3.3.2.2. By Application 7.3.4. Italy Tissue Engineering and Regeneration Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Product 7.3.4.2.2. By Application 7.3.5. United Kingdom Tissue Engineering and Regeneration Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Product 7.3.5.2.2. By Application 8. North America Tissue Engineering and Regeneration Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Product 8.2.2. By Application 8.2.3. By Country 8.3. North America: Country Analysis 8.3.1. United States Tissue Engineering and Regeneration Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Product 8.3.1.2.2. By Application 8.3.2. Mexico Tissue Engineering and Regeneration Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Product 8.3.2.2.2. By Application 8.3.3. Canada Tissue Engineering and Regeneration Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Product 8.3.3.2.2. By Application 9. South America Tissue Engineering and Regeneration Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Product 9.2.2. By Application 9.2.3. By Country 9.3. South America: Country Analysis 9.3.1. Brazil Tissue Engineering and Regeneration Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Product 9.3.1.2.2. By Application 9.3.2. Argentina Tissue Engineering and Regeneration Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Product 9.3.2.2.2. By Application 9.3.3. Colombia Tissue Engineering and Regeneration Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Product 9.3.3.2.2. By Application 10. Middle East and Africa Tissue Engineering and Regeneration Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Product 10.2.2. By Application 10.2.3. By Country 10.3. MEA: Country Analysis 10.3.1. South Africa Tissue Engineering and Regeneration Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Product 10.3.1.2.2. By Application 10.3.2. Saudi Arabia Tissue Engineering and Regeneration Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Product 10.3.2.2.2. By Application 10.3.3. UAE Tissue Engineering and Regeneration Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Product 10.3.3.2.2. By Application 11. Market Dynamics 11.1. Drivers 11.2. Challenges 12. Market Trends & Developments 12.1. Recent Developments 12.2. Product Launches 12.3. Mergers & Acquisitions 13. Global Tissue Engineering and Regeneration Market: SWOT Analysis 14. Porter’s Five Forces Analysis 14.1. Competition in the Industry 14.2. Potential of New Entrants 14.3. Power of Suppliers 14.4. Power of Customers 14.5. Threat of Substitute Product 15. PESTLE Analysis 16. Competitive Landscape 16.1. Organogenesis Inc. 16.1.1. Business Overview 16.1.2. Company Snapshot 16.1.3. Products & Services 16.1.4. Financials (In case of listed companies) 16.1.5. Recent Developments 16.1.6. SWOT Analysis 16.2. Acelity L.P. Inc 16.2.1. Business Overview 16.2.2. Company Snapshot 16.2.3. Products & Services 16.2.4. Financials (In case of listed companies) 16.2.5. Recent Developments 16.2.6. SWOT Analysis 16.3. Zimmer Biomet Holdings Inc. 16.3.1. Business Overview 16.3.2. Company Snapshot 16.3.3. Products & Services 16.3.4. Financials (In case of listed companies) 16.3.5. Recent Developments 16.3.6. SWOT Analysis 16.4. Stryker Corporation 16.4.1. Business Overview 16.4.2. Company Snapshot 16.4.3. Products & Services 16.4.4. Financials (In case of listed companies) 16.4.5. Recent Developments 16.4.6. SWOT Analysis 16.5. Integra LifeSciences Holdings Corporation 16.5.1. Business Overview 16.5.2. Company Snapshot 16.5.3. Products & Services 16.5.4. Financials (In case of listed companies) 16.5.5. Recent Developments 16.5.6. SWOT Analysis 16.6. Medtronic plc 16.6.1. Business Overview 16.6.2. Company Snapshot 16.6.3. Products & Services 16.6.4. Financials (In case of listed companies) 16.6.5. Recent Developments 16.6.6. SWOT Analysis 16.7. Smith & Nephew plc 16.7.1. Business Overview 16.7.2. Company Snapshot 16.7.3. Products & Services 16.7.4. Financials (In case of listed companies) 16.7.5. Recent Developments 16.7.6. SWOT Analysis 16.8. Athersys Inc. 16.8.1. Business Overview 16.8.2. Company Snapshot 16.8.3. Products & Services 16.8.4. Financials (In case of listed companies) 16.8.5. Recent Developments 16.8.6. SWOT Analysis 16.9. Vericel Corporation 16.9.1. Business Overview 16.9.2. Company Snapshot 16.9.3. Products & Services 16.9.4. Financials (In case of listed companies) 16.9.5. Recent Developments 16.9.6. SWOT Analysis 16.10.Osiris Therapeutics, Inc. 16.10.1. Business Overview 16.10.2. Company Snapshot 16.10.3. Products & Services 16.10.4. Financials (In case of listed companies) 16.10.5. Recent Developments 16.10.6. SWOT Analysis 17. Strategic Recommendations 18. About Us & Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社のヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(tissue)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|